<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196193</url>
  </required_header>
  <id_info>
    <org_study_id>T.CR.I.AP.16.4</org_study_id>
    <nct_id>NCT03196193</nct_id>
  </id_info>
  <brief_title>CM Asia Nail With AS2 Without AS2 （AS2 Study）</brief_title>
  <official_title>Randomized Controlled Study Comparing Zimmer Natural Nail System Cephalomedullary Asia Nail With Anterior Support Screw (AS2) Versus Conventional Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare reduction positon maintenance rate at 3 weeks
      post-operatively between patients operated with Anterior Support Screw (AS2) and without AS2
      technique in RCT setting. Total 240 cases(each arm 120 cases) will be enrolled at maximum
      15sites, total study duration is 22months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective： To compare fracture reduction maintenance rate at 2-3weeks post-operatively
      between patients operated with AS2 (investigational group) and patients operated without AS2
      (Control group) using same implant system (ZNN CM Asia, Zimmer Biomet).

      Endpoint： Primary： The rate of reduction position maintenance at 2-3 weeks post-operatively.
      Secondary： Surgery time / fracture type / postoperative reduction position / CT assessment /
      Safety information
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>At surgery, intervention group using ZNN CM Asia with AS2 technique. At surgery, conventional group using ZNN CM Asia without AS2 technique.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>(Investigational group) or ZMM CM Asia without AS2 technique (Control group). The randomization scheme is based on equal numbers per group. The randomization will occur via a random number generator (computer) using a blocked randomization procedure. The block size will not be disclosed to the sites, and the doctor or other health care professional will not have influence on the randomization scheme. Sealed opaque envelopes, which will be prepared based on predetermined randomization assignment, will be provided to each study site before study initiation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of AS2 technique: Maintenance rate of reduction position</measure>
    <time_frame>Postoperative 2-3 week</time_frame>
    <description>The maintenance rate of reduction position at 2-3 weeks post-operatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgery time</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Surgery time from skin incision to closure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT Assessment</measure>
    <time_frame>Immediate postoperative and 2-3 weeks</time_frame>
    <description>Postoperative CT scanning to evaluate fracture reduction position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Information: Any adverse events (including device related, non-device related, procedure related, non-procedure related)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Any adverse events (including device related, non-device related, procedure related, non-procedure related)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Information: Any adverse events (including device related, non-device related, procedure related, non-procedure related)</measure>
    <time_frame>Up to 3 weeks (Up to 16 weeks (Option))</time_frame>
    <description>Any adverse events (including device related, non-device related, procedure related, non-procedure related)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Trochanteric Fracture of Femur</condition>
  <arm_group>
    <arm_group_label>ZNN CM Asia with AS2 technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.
Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZNN CM Asia without AS2 technique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open Reduction and Internal Fixation</intervention_name>
    <description>Fractured bone fragments are reduced and stabilized by intramedullary nail.</description>
    <arm_group_label>ZNN CM Asia with AS2 technique</arm_group_label>
    <arm_group_label>ZNN CM Asia without AS2 technique</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ZNN CM Asia</intervention_name>
    <description>Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.</description>
    <arm_group_label>ZNN CM Asia with AS2 technique</arm_group_label>
    <arm_group_label>ZNN CM Asia without AS2 technique</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anterior Support Screw</intervention_name>
    <description>Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.</description>
    <arm_group_label>ZNN CM Asia with AS2 technique</arm_group_label>
    <other_name>ACE 4.5/5.0mm cannulated lag-screw</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be eligible to participate in this study, a subject must meet all of the
        following criteria.

          -  Eligible for intramedullary nailing.

          -  Fracture type is classified as 3-partB or 4-part fracture in 3D-CT classification
             (Nakano), and combination with a subtype P in lateral classification (Ikuta) at
             preoperative CT assessment.(In the case of classified in X-ray at preoperative:
             Classified as Type 4 or Type 5 in Jensen classification, and combination of subtype P
             in lateral classification (Ikuta))

          -  Japanese Male or female

          -  &gt; 20 years of age

          -  Primary closed intertrochanteric fracture of the femur

          -  Subjects willing to return for follow-up evaluations.

        Exclusion Criteria:

        A potential subject who meets any of the following criteria will be excluded from
        participation in this study.

          -  Patient who cannot take CT image within 3 days and 2-3weeks after surgery.

          -  Uncooperative patient or patient with neurologic disorders who are incapable of
             following directions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi Maehara, MD, Ph. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kagawa Rosai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kure Kyosai Hospital</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyooka Hospital</name>
      <address>
        <city>Toyooka</city>
        <state>Hyogo</state>
        <zip>668-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasugai Municipal Hospital</name>
      <address>
        <city>Aichi</city>
        <state>Kasugai</state>
        <zip>486-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoshigaoka Medical Center</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Numazu City Hospital</name>
      <address>
        <city>Numazu</city>
        <state>Shizuoka</state>
        <zip>410-0302</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Takaoka Hospital</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <zip>933-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Central Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Central Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>950-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Red Cross Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8607</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Rosai Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saga Pref. Medical Centre Koseikan</name>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Fractures</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03196193/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

